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density lipoprotein cholesterol levels and
microvascular endothelial function in patients
with rheumatoid arthritis: a Pilot Study
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Background: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality from cardiovascular
disease (CVD). This can be only partially attributed to traditional CVD risk factors such as dyslipidaemia and their
downstream effects on endothelial function. The most common lipid abnormality in RA is reduced levels of
high-density lipoprotein (HDL) cholesterol, probably due to active inflammation. In this longitudinal study we
hypothesised that anti-tumor necrosis factor-α (anti-TNFα) therapy in patients with active RA improves HDL
cholesterol, microvascular and macrovascular endothelial function.
Methods: Twenty-three RA patients starting on anti-TNFα treatment were assessed for HDL cholesterol level, and
endothelial-dependent and -independent function of microvessels and macrovessels at baseline, 2-weeks and
3 months of treatment.
Results: Disease activity (CRP, fibrinogen, DAS28) significantly decreased during the follow-up period. There was an
increase in HDL cholesterol levels at 2 weeks (p< 0.05) which was paralleled by a significant increase in microvascular
endothelial-dependent function (p< 0.05). However, both parameters returned towards baseline at 12 weeks.
Conclusion: Anti-TNFα therapy in RA patients appears to be accompanied by transient but significant improvements
in HDL cholesterol levels, which coexists with an improvement in microvascular
endothelial-dependent function.
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease, characterised by erosive symmetrical polyarthritis. It
is the most common inflammatory arthritis, affecting ap-
proximately 0.8% of the adult population. RA is also asso-
ciated with increased morbidity and mortality from
cardiovascular disease (CVD) [1], which appears to be of
equal frequency and severity as in those with diabetes
mellitus of similar duration [2]. This could be partially* Correspondence: aamer.sandoo@dgh.nhs.uk
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reproduction in any medium, provided the orattributed to an increased prevalence of traditional CVD
risk factors such as hypertension, dyslipidaemia and obes-
ity [3]. In particular, the prevalence of dyslipidaemia in RA
is high [4], it is evident in both early [5] and advanced RA
[6], and may even associate with some RA susceptibility
genes [7] and precede the development of RA [8].
The most common lipid abnormality in RA is reduced
levels of high-density lipoprotein (HDL) cholesterol
[5,9]. HDL prevents oxidation of low density lipoprotein
(LDL) cholesterol and is involved in cellular efflux of
accumulated LDL particles in the vasculature, which in
turn prevents foam cell accumulation and subsequent
endothelial dysfunction (ED) [10]. Inflammation can re-
duce the anti-atherogenic and anti-oxidant properties of
HDL by altering the function of key enzymes important tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cytokines such as tumor necrosis factor alpha (TNFα) can
reduce hepatic lipase concentration [11]. Hepatic lipase
alters the size of HDL particles to allow greater uptake of
cholesterol from other cells. Changes to the enzymatic
content of HDL (i.e. reduced paraoxonase) also results
from inflammation, and transforms HDL into a pro-
oxidant and pro-inflammatory molecule [12,13]. Inhibition
of TNFα through treatment of RA patients can increase
HDL levels [14], as well as reducing disease activity and
delaying or even reversing progressive joint damage [15].
Importantly, Anti-TNFα therapy may also reduce cardio-
vascular mortality in RA [16], possibly as a result of a re-
duction in inflammation [17].
HDL also exerts specific effects in the vasculature in-
cluding the stimulation of nitric oxide (NO) in endothelial
cells, the reduction of TNFα-mediated superoxide release
and repair of damaged blood vessels [18–21]. A number of
cross-sectional studies have shown that HDL particle size
inversely associates with microvascular and macrovascular
ED in a variety of populations including healthy individuals,
diabetics [10,22,23] as well as RA patients [24–26]. Further-
more, a systematic review of the literature revealed that
HDL levels are inversely associated with the risk for stroke
and carotid artery atherosclerosis in various patient groups
[27]. Collectively, these findings suggest that HDL may be
an important determinant of vascular health in any popula-
tion, including RA.
The objective of the present longitudinal study was to
evaluate the effect of anti-TNFα therapy on HDL choles-
terol levels and to explore associations between changes
in HDL cholesterol levels with contemporary changes in




Twenty three consecutive patients with RA who were due
to start anti-TNFα therapy on clinical indication (UK
guidelines [28]) were recruited from the Rheumatology
outpatient clinics of the Dudley Group NHS Foundation
Trust, UK. All patients met the retrospective application
of the 1987 revised RA criteria of the American College of
Rheumatology [29]. The exclusion criterion was: previ-
ously confirmed acute coronary syndrome or established
CVD. The study had Research Ethics Committee and Re-
search and Development approval from Birmingham, East,
North and Solihull Research Ethics Committee and all
participants gave their written informed consent accord-
ing to the Declaration of Helsinki.
Study protocol
Anti-TNFα patients attended a thermoregulated (22±0.9°C)
vascular laboratory after a 12 hour overnight fast between7:00 am and 11:00 am for 3 separate visits: prior to starting
anti-TNFα (pre-treatment), 2 weeks and 3 months after ini-
tiation of treatment. Fifteen (65%) of the anti-TNFα patients
were started on 40 mg of adalimumab taken fortnightly, six
(26%) on 50 mg of etanercept taken weekly and two (9%) on
infliximab with a dosage of 3 mg/kg according to standard
dose administration protocol. There was no change in any
of these medications or their doses during the follow up
period. Assessments at 2 weeks and 3 months were per-
formed before the patient received the next dose of their
drug. Patients were asked to refrain from exercise 24 hours
before the session and from smoking 12 hours before the
session.
Metabolic and serological assessments
All patients underwent evaluation of their medical history
and general demographics, examination of height, weight
and body mass index (BMI). Blood tests were carried out
in the biochemistry laboratories at Russells Hall Hospital,
UK. Serum levels of total cholesterol (TC), high-density
lipoprotein cholesterol (HDL), triglycerides (TG) and C-
reactive protein (CRP) were measured using the Vitros
5.1chemistry system (www.orthoclinical.com). Levels of
erythrocyte sedimentation rate (ESR) were determined
using the Westergren method via a Starrsed Compact
(Mechatronics BV, Netherlands). Fibrinogen was mea-
sured by photo-optical clot detection based on the Clauss
quantitative fibrinogen method, using an automated co-
agulation analyser (ACL Futura Plus, Instrumentation La-
boratory, UK). On each occasion disease activity was
assessed with disease activity score in 28 joints (DAS28),
along with functional ability using Anglicised version of
the Stanford Health Assessment Questionnaire (HAQ),
and physical activity levels using International Physical
Activity Questionnaire (IPAQ) [30–32]. Concentration of
the TNFα cytokine was measured from stored serum sam-
ples using FlowCytomix kits (BenderMed Systems GmbH,
Vienna, Austria). Fluorescent beads were coated with
antigen-specific antibodies for the cytokine and incubated
with the sample. The assay follows the same principle as a
sandwich immunoassay. Flow-cytometry (Bender MedSys-
tems GMBH, Vienna, Austria) was used to differentiate
bead populations by their size and fluorescent signature.
Microvascular endothelial function
Endothelial function of the microvasculature was assessed
non-invasively by a single observer (AS), using Laser Doppler
Imaging (LDI) (Moor LDI 2 SIM, Moor Instruments Ltd,
Devon, UK) with iontophoresis of 1% acetylcholine (ACh,
endothelium-dependent) and 1% sodium-nitroprusside (SNP,
endothelium-independent) (Sigma Chemical Co, Montvale,
New Jersey, USA) in 0.5 ml of saline. The technique was per-
formed according to previously established guidelines [33] and
has been described in detail previously [34]. Briefly, after a
Table 1 Baseline characteristics of the RA patients.
RA Patients
General Characteristics
Age (years) 54 ± 15
Sex female N (%) 15 (65)
Height (cm) 165± 8
BMI (kg/m2) 30 ± 6
Disease-related Characteristics
RF Positive N (%) 20 (87)
Disease duration (years) 11 ± 11
CVD Risk Factors
Family history of CVD 12 (40)
Diabetes 1 (3)
Hypertension 6 (20)
High Cholesterol 6 (20)




Never smoked 11 (48.8)
Previous smokers 7 (30)
Current smokers 5 (22)
Rheumatologic Medications
Methotrexate (%) 16 (70)
Glucocorticosteroids (%) 6 (26)
Medium dose GC (≥7.5 mg) (%) 13 (56)
NSAIDs (%) 6 (26)
Cardiovascular Medications
Anti-hypertensive treatment (%) 5 (22)
Anti-hypercholesterolemic (%) 4 (17)
Results are expressed as Number (%) and mean ± standard deviation. Diabetes =
fasting glucose>7 mmol/l and/or oral hypoglycaemic medication or insulin use;
hypertension = SBP >140 mmHg, DBP >90 mmHg or use of anti-hypertensive’s; high
cholesterol = fasting cholesterol>4.1 mmol/l or use of anti-hypercholesterolemics;
insulin resistance = homeostasis model assessment ≥2.5 or quantitative insulin
sensitivity check index ≤0.333; overweight: BMI≥23-27.9; obese: BMI≥28. BMI: body
mass index, RF: rheumatoid factor.
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the vasoactive agents using a 30 μA current, followed by two
scans during recovery. This technique has an intra-observer
co-efficient of variation (CV) for ACh and SNP of 6.5% and
5.9% respectively in our laboratory.
Macrovascular endothelial function
Assessment of macrovascular endothelial-dependent
function was performed using flow-mediated dilatation
(FMD) with high-resolution ultrasonography of the
brachial artery (Acuson Antares ultrasound system,
Siemens PLC, Camberley, UK) according to previously
established guidelines [35] and has been described in
detail previously [34]. Following ten minutes of rest,
endothelium-independent responses were examined by
administration of 500 microgram sublingual glyceryl-
trinitrate (GTN) tablet (Alpharma, Barnstaple, UK)
while the brachial artery was imaged continuously for
five minutes. The intra-observer CV was 10.7% for
FMD and 11.8% for GTN assessments respectively. For
all vascular tests, endothelial function was expressed as
the percentage increase in perfusion or diameter from
baseline, and all analysis was carried out offline by AS
who was blinded to the identity and time point of the
patient.
Statistical analysis
Statistical analysis was performed using SPSS18 (SPSS Inc,
Chicago, Illinois). Variables were tested for normality by
the Kolmogorov-Smirnov test. Means and standard devia-
tions (SD) were calculated for normally distributed con-
tinuous variables and proportions for categorical variables.
Log transformation was performed for positively skewed
variables as appropriate. The effect of anti-TNFα treat-
ment on blood lipid parameters and vascular indices (con-
tinuous variables) was tested using repeated measures
analyses of variance (ANOVA). Where appropriate, LSD
post hoc analyses were conducted. The change in lipid and
inflammatory parameters as well as endothelial function at
2 and 12 weeks was calculated by subtracting the pre-
treatment baseline values from the values obtained at 2
and 12 weeks. Pearson correlations were used to examine
whether changes in endothelial function related to changes
in lipids or disease-related inflammation. Endothelial func-
tion and lipid parameters did not differ between the three
different types of anti-TNFα treatment at any time point,
therefore all treatments were analysed together.
Results
Baseline characteristics
The baseline characteristics as well as rheumatologic
and cardiovascular medications for study patients are
shown in Table 1. There was no change in any of these
drugs or their dose during the follow-up period.Treatment with anti-TNFα
Table 2 shows the lipid profile, disease activity, dyslipidae-
mia risk factors, and vascular measurements over the
course of the study. During follow up of this group, there
was, as expected, a significant reduction in all of the mar-
kers of disease activity including CRP, ESR, fibrinogen,
DAS28 and HAQ. However, ESR levels were no longer
significantly different from baseline at 3 months. No
changes in TNFα concentration were found in response
to treatment. HDL was the only lipid parameter whose
levels increased significantly after 2 weeks of treatment,
before values returned towards baseline at 3 months
(Table 2). The other lipid parameters did not show
Table 2 Lipid profile, disease activity, dyslipidaemia risk factors, and vascular measurements across the three visits for
patients starting anti-TNFα therapy.
Baseline 2 weeks 3 months P-value
Lipid Profile
TC (mmol/l) 4.7 ± 1.0 4.9 ± 1.1 4.8 ± 0.9 0.170
HDL cholesterol (mmol/l) 1.4 ± 0.3 1.5 ± 0.3† 1.4 ± 0.3 0.014
TG (mmol/l) 1.4 ± 0.6 1.5 ± 0.7 1.6 ± 0.9 0.236
Disease Activity
CRP (mg/l) 10 (4 to 14) 3 (2.9 to 6)† 5 (2.9 to 10)† <0.001
ESR (mmhr) 16 (9–34) 10 (5–21)† 17 (5–27) 0.003
Fibrinogen (g/l) 5.1 ± 1.0 4.2 ± .75 † 4.3 ± .91† <0.001
DAS 28 4.22 ± 0.94 2.71 ± 1.38† 2.80 ± 1.30† <0.001
HAQ 2.1 ± 0.5 1.3 ± 0.9 † 1.3 ± 0.9 † <0.001
TNFα cytokine (pg/ml)* 3.27 (0–65) 16.2 (0–73) 33.1 (0–68) 0.452
Dyslipidaemia Risk Factors
BMI (kg/m2) 30.2 ± 6.1 30.3 ± 6.1 30.3 ± 6.2 0.747
IPAQ (met min/wk) 2850 ± 5451 2914± 3551 2503± 3163 0.625
Vascular Measurements
Microvascular endothelial-dependent and endothelial-independent function
ACh (%) 319 ± 217 437± 247 † 348 ± 209 0.017
SNP (%) 252 ± 126 288± 150 261 ± 152 0.314
Macrovascular endothelial-dependent and endothelial-independent function
FMD (%) 9.4 ± 6.9 12.0 ± 9.6 12.0 ± 8.1 0.214
GTN (%) 22.6 ± 7.5 23.2 ± 7.0 23.8 ± 7.2 0.737
Results expressed as mean ± SD or median (interquartile range) as appropriate.
TC: total cholesterol, HDL: high density lipoprotein, TG: triglycerides, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, DAS28: disease activity score,
HAQ: health assessment questionnaire, TNFα: tumor necrosis factor alpha, BMI: body mass index, IPAQ: international physical activity questionnaire, ACh:
acetylcholine-mediated dilatation, SNP: sodium nitroprusside-mediated dilatation, FMD: flow-mediated-dilatation, GTN: glyceryl trinitrate-mediated dilatation.
†p< 0.05 when compared to baseline visit. *Data for 21 patients only.
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TNFα treatment.
Of the vascular measurements, only microvascular
endothelial-dependent function (ACh) exhibited a significant
change (increased dilatation) after 2 weeks of anti-TNFα
therapy compared to baseline measurements: 437±247% vs.
319±217% respectively, p=0.001 (Table 2). None of the
other vascular assessments demonstrated significant changes
either at 2 weeks or 3 months of follow-up (Table 2). Pear-
son correlations did not reveal any significant associations
between change in microvascular endothelial function and
change in HDL cholesterol at 2 weeks (r (21)= -.03, p= .89).
There were no significant correlations between changes in
HDL cholesterol with changes in other vascular or inflam-
matory parameters.
Discussion
The present study revealed a transient improvement in
HDL cholesterol levels following 2 weeks of treatment
with anti-TNFα theraphy which returned to baseline levels
after 3 months in RA patients with active disease who hadnewly started anti-TNFα treatment. A concomitant in-
crease in microvascular endothelial-dependent function
but not macrovascular endothelial-dependent function
was also observed in these patients.
To our knowledge the current study is the first to report
the effects of anti-TNFα in RA patients who underwent
simultaneous measurements of their lipid profile as well
as microvascular and macrovascular endothelial function.
Previous studies that measured lipid parameters and
endothelial function in response to anti-TNFα treatment
have examined endothelial function in the macrocircula-
tion only [36] or have focused on drugs targeting other in-
flammatory pathways [37,38], and report conflicting
findings. Irace and colleagues [36] reported a transient in-
crease in macrovascular endothelial-dependent function
immediately after infusion of infliximab at 0, 2 and
6 weeks, however, HDL levels decreased. It was suggested
that during inflammation, HDL particles bind with TNFα
and buffer the cytokine from the circulation. Inhibition of
TNFα with infliximab could reduce TNFα-HDL- com-
plexes and consequently reduce circulatory levels of HDL
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terol levels was reported in RA patients following short-
term (2 weeks and 6 weeks) treatment with infliximab
which was correlated with reductions in disease-related
inflammation [39]. Similarly, administration of the anti-
CD20 agent, rituximab, led to a significant improvement
in HDL cholesterol levels and macrovascular endothelial-
dependent function after 16 weeks [37] and 24 weeks of
treatment [40], both of which are time points associated
with maximum efficacy for rituximab in reducing inflam-
mation [41]. Inflammation can reduce HDL levels [42]
and its core components, such as the anti-oxidant enzyme
paraoxonase [12,13]. It is therefore possible that in the
present study, the increase in HDL cholesterol reflected
the acute reduction in global inflammation at 2 weeks,
with stabilisation of inflammation at 3 months resulting in
no further changes in the lipid profile [14].
The transient improvement in microvascular endothelial-
dependent function mirrored the increase in HDL choles-
terol at 2 weeks with the majority of other risk factors
(including physical activity levels) remaining unchanged.
HDL cholesterol can exert acute effects in the vasculature,
including a reduction in TNFαmediated superoxide release,
increased production of endothelial progenitor cells, and
stimulation of NO in endothelial cells [18–21] all of which
increase endothelial dependent vasodilatation [18]. Given
that both HDL cholesterol levels as well as its anti-oxidant
ability can increase with administration of anti-TNFα in RA
[14,43], it is likely that the improvement in microvascular
endothelial-dependent function after 2 weeks of treatment
with anti-TNFα was mediated by the increased HDL chol-
esterol levels. Nevertheless, no association was apparent be-
tween baseline HDL cholesterol and endothelial function or
changes in HDL cholesterol levels and endothelial function
following treatment. The absence of any associations in the
present study may be due to the small sample size. To our
knowledge, no other studies have reported associations with
endothelial function and HDL cholesterol in RA. Further
work exploring such associations in a larger sample size is
required.
The finding that microvascular function, but not
macrovascular function improved following treatment
might reflect the heterogeneity of these vascular beds
from each other [44]. We have previously shown that
microvascular and macrovascular endothelial function
are independent from each other in patients with RA
[45]. The microvasculature makes up a much larger pro-
portion than macrovessels and may therefore respond
earlier to changes in CVD risk factors or other injurious
stimuli [46]. Indeed, it has been hypothesised that the
inflammatory response as a result of hypercholesterol-
emia may be initiated by endothelial activation in the
microvasculature [46]. Consequently, it is possible that
even small changes in blood lipids could have a greatereffect on microvascular endothelial-dependent function.
There is also some evidence that in other clinical condi-
tions like diabetes, microvascular dysfunction develops
independently of macrovascular dysfunction [46], and
may even contribute to the development of macrovascu-
lar disease [47].
The majority of previous studies examining the effect of
anti-TNFα on the lipid profile have included patients trea-
ted with infliximab [36,48], and there is little evidence on
the effects of other anti-TNFα agents. Different anti-TNFα
agents have unique molecular structures, modes of action
and half lives and could therefore differentially impact on
inflammation and the lipid profile [14]. In the current
study only two patients were receiving infliximab infu-
sions, with the majority of patients receiving adalimumab
(n= 15) or etanercept (n= 6). Consequently, the effect of
each agent on the lipid profile and endothelial function
could not be characterised due to the small sample size of
the study. Further studies which include a large sample of
patients on all types of anti-TNFα agents are required to
delineate their individual effects on CVD risk factors and
endothelial function.
There is evidence that Inflammation might affect the
size of lipid particles, as TNFα can increase the HDL par-
ticle size reducing its effectiveness in reverse cholesterol
transport [11,49]. This has profound implications on the
assessment of blood lipids as the size of the HDL particle
may be of equal (or greater) importance to HDL choles-
terol levels in the circulation. Furthermore, a number of
studies have demonstrated that the protein content of
HDL particles is altered during chronic RA disease-related
inflammation [50,51]. In particular, there is an increase in
acute phase proteins and proteins involved in the comple-
ment cascade which results in HDL becoming pro-
inflammatory in RA [50]. In addition, RA patients exhibit-
ing pro-inflammatory HDL have greater inflammatory
proteins within the HDL molecule when compared to
patients exhibiting anti-inflammatory HDL and healthy
controls, and pro-inflammatory HDL complexes associate
with higher DAS28 and presence of erosive disease [51].
These findings highlight the need for future studies which
measure the effects of lipid sub-fractions as well as the
protein content of HDL molecules on CVD risk in RA.
Even though the sample size was not large, it had suffi-
cient power to detect differences in HDL and vascular
parameters. Post hoc power analyses using GPower3
[52] with significance set at .05 revealed that, given the
sample size and effect size, the obtained power was .94
to detect differences in HDL cholesterol, .99 to detect
differences in microvascular endothelial function, and
.98 to detect differences in macrovascular endothelial
function. A limitation of the study was the absence of a
control group of RA patients not receiving anti-TNFα. It
was decided that it would be unethical to withhold
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TNFα, and including patients receiving other disease
modifying anti-rheumatic drugs would not be suitable,
as relative to the anti-TNFα group, these patients would
have much lower levels of baseline inflammation.
Conclusion
In conclusion, the present study revealed that treatment
with anti-TNFα resulted in a transient improvement in
HDL cholesterol levels and a concomitant improvement
in microvascular but not in macrovascular endothelial
function. This was possibly mediated by a favourable ef-
fect of HDL cholesterol on microvascular endothelial
function. Further prospective studies utilising large sam-
ple sizes are required to confirm these findings.
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